Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call

Rhea-AI Summary

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will announce its first quarter 2021 financial results on May 5, 2021. A conference call will follow at 8:00 a.m. ET to discuss results and provide a business update. Dial-in numbers are 866-300-4091 (domestic) and 703-736-7433 (international) with conference ID 2777865. The company focuses on innovative therapies for eye diseases, utilizing its AMPPLIFY® drug delivery technology in products like EYSUVIS® for dry eye and INVELTYS® for postoperative inflammation. Visit kalarx.com for more information.

Positive

• Scheduled Q1 2021 financial results announcement on May 5, 2021.
• Management will provide a business update during the conference call.

Negative

• None.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 2777865. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY^® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS^® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS^® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005101/en/

FAQ

When will Kala Pharmaceuticals report its Q1 2021 financial results?

Kala Pharmaceuticals will report its Q1 2021 financial results on May 5, 2021.

What time is the Kala Pharmaceuticals conference call on May 5, 2021?

The conference call will take place at 8:00 a.m. ET.

How can I access the conference call for Kala Pharmaceuticals?

You can access the call by dialing 866-300-4091 (domestic) or 703-736-7433 (international) using conference ID 2777865.

What is the focus of Kala Pharmaceuticals' product development?

Kala Pharmaceuticals focuses on innovative therapies for diseases of the eye, utilizing AMPPLIFY® drug delivery technology.